Figures & data
Figure 1. Baseline MACE rate in ASCVD population plotted against incremental cost-effectiveness of PCSK9 inhibitor in treated but uncontrolled ASCVD patients. We have not changed any of the model inputs or their resulting ICERs except for the calculation of the ICER for Jena 2016, which was a value model not a cost-effectiveness model. The ratio of QALYs to life-years from Kazi 2016 was applied to the calculation of life-years from Jena 2016 to calculate an ICER by QALYs. MACE: major adverse cardiac events.
